These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 26502667)

  • 21. 131I-MIBG therapy of neural crest tumours (review).
    Troncone L; Rufini V
    Anticancer Res; 1997; 17(3B):1823-31. PubMed ID: 9179240
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimizing MIBG therapy of neuroendocrine tumors: preclinical evidence of dose maximization and synergy.
    Mairs RJ; Boyd M
    Nucl Med Biol; 2008 Aug; 35 Suppl 1():S9-20. PubMed ID: 18707637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of Repeated
    Yoshinaga K; Abe T; Okamoto S; Uchiyama Y; Manabe O; Ito YM; Tamura N; Ito N; Yoshioka N; Washino K; Shinohara N; Tamaki N; Shiga T
    J Nucl Med; 2021 May; 62(5):685-694. PubMed ID: 33067337
    [No Abstract]   [Full Text] [Related]  

  • 24. 131I MIBG therapy in neuroblastoma: mechanisms, rationale, and current status.
    Tepmongkol S; Heyman S
    Med Pediatr Oncol; 1999 Jun; 32(6):427-31; discussion 432. PubMed ID: 10358701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Therapeutic advances of nuclear medicine in oncology].
    Valdés Olmos RA; Hoefnagel CA; Bais E; Boot H; Taal B; de Kraker J; Vote PA
    Rev Esp Med Nucl; 2001 Dec; 20(7):547-57. PubMed ID: 11709141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 131I/123I-metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging.
    Bombardieri E; Giammarile F; Aktolun C; Baum RP; Bischof Delaloye A; Maffioli L; Moncayo R; Mortelmans L; Pepe G; Reske SN; Castellani MR; Chiti A;
    Eur J Nucl Med Mol Imaging; 2010 Dec; 37(12):2436-46. PubMed ID: 20644928
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [131I]MIBG radionuclide therapy in carcinoid syndrome.
    Taal BG; Zuetenhorst H; Valdés Olmos RA; Hoefnagel CA
    Eur J Surg Oncol; 2002 Apr; 28(3):243. PubMed ID: 11944956
    [No Abstract]   [Full Text] [Related]  

  • 28. MIBG and radiolabeled octreotide in neuroendocrine tumors.
    Hoefnagel CA
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):137-9. PubMed ID: 9002773
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Minimizing nuclear medicine technologist radiation exposure during 131I-MIBG therapy.
    Turpin BK; Morris VR; Lemen L; Weiss BD; Gelfand MJ
    Health Phys; 2013 Feb; 104(2 Suppl 1):S43-6. PubMed ID: 23287519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 131I-Metaiodobenzylguanidine therapy in children with advanced neuroblastoma.
    DuBois SG; Matthay KK
    Q J Nucl Med Mol Imaging; 2013 Mar; 57(1):53-65. PubMed ID: 23474635
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced tumor uptake in neuroendocrine tumors after intraarterial application of 131I-MIBG.
    Brogsitter C; Pinkert J; Bredow J; Kittner T; Kotzerke J
    J Nucl Med; 2005 Dec; 46(12):2112-6. PubMed ID: 16330578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted radiotherapy of multicell neuroblastoma spheroids with high specific activity [125I]meta-iodobenzylguanidine.
    Roa WH; Miller GG; McEwan AJ; McQuarrie SA; Tse J; Wu J; Wiebe LI
    Int J Radiat Oncol Biol Phys; 1998 May; 41(2):425-32. PubMed ID: 9607361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nuclear medicine therapy of pheochromocytoma and paraganglioma.
    Troncone L; Rufini V
    Q J Nucl Med; 1999 Dec; 43(4):344-55. PubMed ID: 10731785
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms.
    Pasieka JL; McEwan AJ; Rorstad O
    Surgery; 2004 Dec; 136(6):1218-26. PubMed ID: 15657579
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution.
    Barrett JA; Joyal JL; Hillier SM; Maresca KP; Femia FJ; Kronauge JF; Boyd M; Mairs RJ; Babich JW
    Cancer Biother Radiopharm; 2010 Jun; 25(3):299-308. PubMed ID: 20578835
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Guidelines for 131I-meta-iodobenzylguanidine therapy.
    Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):BP23-6. PubMed ID: 12723562
    [No Abstract]   [Full Text] [Related]  

  • 37. The current status of radioiodinated metaiodobenzylguanidine therapy of neuro-endocrine tumors.
    Shapiro B; Sisson JC; Shulkin BL; Gross MD; Zempel S
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):55-7. PubMed ID: 9002750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nothing but NET: a review of norepinephrine transporter expression and efficacy of 131I-mIBG therapy.
    Streby KA; Shah N; Ranalli MA; Kunkler A; Cripe TP
    Pediatr Blood Cancer; 2015 Jan; 62(1):5-11. PubMed ID: 25175627
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Whole-body iodine-131 metaiodobenzylguanidine imaging for detection of bone metastases in patients with paraganglioma: comparison with bone scintigraphy.
    Inoue T; Yoshinaga K; Morita K; Shiga T; Kanegae K; Hirata K; Okamoto S; Tamaki N
    Ann Nucl Med; 2007 Jul; 21(5):307-10. PubMed ID: 17634850
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A gene therapy/targeted radiotherapy strategy for radiation cell kill by.
    Boyd M; Mairs RJ; Cunningham SH; Mairs SC; McCluskey A; Livingstone A; Stevenson K; Brown MM; Wilson L; Carlin S; Wheldon TE
    J Gene Med; 2001; 3(2):165-72. PubMed ID: 11318115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.